JP5744919B2 - インスリン投与の際の安全警告を備えた分析物試験方法及びシステム - Google Patents
インスリン投与の際の安全警告を備えた分析物試験方法及びシステム Download PDFInfo
- Publication number
- JP5744919B2 JP5744919B2 JP2012554980A JP2012554980A JP5744919B2 JP 5744919 B2 JP5744919 B2 JP 5744919B2 JP 2012554980 A JP2012554980 A JP 2012554980A JP 2012554980 A JP2012554980 A JP 2012554980A JP 5744919 B2 JP5744919 B2 JP 5744919B2
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- user
- microprocessor
- time frame
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 231
- 229940125396 insulin Drugs 0.000 title claims description 117
- 102000004877 Insulin Human genes 0.000 title claims description 115
- 108090001061 Insulin Proteins 0.000 title claims description 115
- 239000012491 analyte Substances 0.000 title description 10
- 238000010998 test method Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims description 80
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 67
- 239000008103 glucose Substances 0.000 claims description 67
- 150000001720 carbohydrates Chemical class 0.000 claims description 42
- 238000004364 calculation method Methods 0.000 claims description 38
- 206010012601 diabetes mellitus Diseases 0.000 claims description 32
- 238000012360 testing method Methods 0.000 claims description 28
- 239000008280 blood Substances 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 21
- 238000005259 measurement Methods 0.000 claims description 21
- 230000006870 function Effects 0.000 claims description 20
- 206010022489 Insulin Resistance Diseases 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 55
- 230000008569 process Effects 0.000 description 46
- 235000014633 carbohydrates Nutrition 0.000 description 34
- 238000007726 management method Methods 0.000 description 20
- 238000012937 correction Methods 0.000 description 18
- 238000013523 data management Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 7
- 229940127560 insulin pen Drugs 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 4
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000001019 normoglycemic effect Effects 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 2
- -1 Novolog Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 101100406385 Caenorhabditis elegans ola-1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical group [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940038661 humalog Drugs 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940060975 lantus Drugs 0.000 description 1
- 229940102988 levemir Drugs 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229940112879 novolog Drugs 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/157—Devices characterised by integrated means for measuring characteristics of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3561—Range local, e.g. within room or hospital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3592—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Primary Health Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Optics & Photonics (AREA)
- Nutrition Science (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- External Artificial Organs (AREA)
- Accommodation For Nursing Or Treatment Tables (AREA)
Description
式1 GCD=(現在のBG−目標BG)×インスリン感受性係数
式2 CCDのためのインスリンボーラス量=炭水化物概算×インスリン対炭水化物比
Claims (31)
- メモリ、ディスプレイ、クロック、及びユーザーインターフェースに接続されたマイクロプロセッサを有する糖尿病管理ユニットを使用してユーザーのインスリン投与の際の安全機能を提供する方法であって、前記方法が、
1日のうちのインスリンボーラス投与のための複数の時間枠から前記1日のうちのある時間枠を選択する工程と、
前記マイクロプロセッサを使用して、前記選択された時間枠内の前記ユーザーのためのインスリンボーラスを計算する工程と、
前記マイクロプロセッサを使用して、前記選択された時間枠を、前記マイクロプロセッサのクロックによって維持されている現在の時間枠と比較する工程と、
前記計算のために選択された時間枠が前記クロックの前記現在の時間枠の範囲外の場合は、前記ユーザーに警告を通知する工程と、を含む、方法。 - グルコース測定を行い、測定値を前記1日の間の時間枠に関連するものとしてフラグ付けすることを更に含む、請求項1に記載の方法。
- 24時間の時間枠内の少なくともある範囲の時間間隔を、前記複数の時間枠のうちの1つとして設定することを更に含む、請求項1に記載の方法。
- 前記設定することが、24時間の時間枠のうちの朝の期間、午後の期間、晩の期間、及び夜の期間に関する対応する時間間隔を画定することを含む、請求項3に記載の方法。
- 前記朝の期間がおよそ5am〜およそ11amと事前に画定され、前記午後の期間がおよそ11am〜およそ5pmと事前に画定され、前記晩の期間がおよそ5pm〜およそ10pmと事前に画定され、前記夜の期間がおよそ10pm〜およそ5amと事前
に画定される、請求項4に記載の方法。 - 前記計算することが、前記複数の時間枠のそれぞれごとにインスリン対炭水化物比を指定することを含む、請求項1に記載の方法。
- 前記計算することが、前記複数の時間枠のそれぞれに、約1単位:約50gを包含する初期インスリン対炭水化物比を指定することを含む、請求項1に記載の方法。
- 前記指定することが、前記インスリン対炭水化物比の定義を通知することを更に含む、請求項7に記載の方法。
- 前記計算することが、前記複数の時間枠のそれぞれごとにインスリン感受性値を指定することを含む、請求項1に記載の方法。
- 前記計算することが、前記複数の時間枠のそれぞれごとに、約1単位:1デシリットル当たり約150mgを包含する初期インスリン感受性値を指定することを含む、請求項1に記載の方法。
- 前記指定することが、前記インスリン感受性値の画定を通知することを更に含む、請求項10に記載の方法。
- 前記計算することが、前記複数の時間枠のそれぞれごとに目標血糖値を指定することを含む、請求項1に記載の方法。
- 前記計算することが、前記複数の時間枠のそれぞれごとに、1デシリットル当たり約240mgを包含する初期目標血糖値を指定することを含む、請求項1に記載の方法。
- 前記指定することが、前記目標血糖値の画定を通知することを更に含む、請求項13に記載の方法。
- 前記計算することが、前記複数の時間枠のそれぞれごとに、インスリン対炭水化物比、インスリン感受性係数値、及び目標血糖値を指定することを含む、請求項1に記載の方法。
- 前記通知することが、前記マイクロプロセッサの現在時刻が前記選択された時間枠の範囲外であるという文字情報を前記ディスプレイに表示することを含む、請求項1に記載の方法。
- 前記通知することが、前記フラグ付けが選択された時間枠と一致しないという文字情報を前記ディスプレイに表示することを含む、請求項2に記載の方法。
- 前記選択することが、前記複数の時間枠を予め設定することを含む、請求項1に記載の方法。
- 前記計算することは、測定されたグルコースの濃度が所定の値よりも低い場合は、行わない、請求項2に記載の方法。
- 糖尿病管理システムにおいて、
グルコース試験ストリップと、
糖尿病管理ユニットと、を含み、前記糖尿病管理ユニットが、
前記グルコース試験ストリップを収容するように構成された試験ストリップポートを有するハウジングと、
複数のユーザーインターフェースボタンと、
前記試験ストリップポートに接続されて、前記試験ストリップの上に沈着したユーザーの生理液中の測定されたグルコースの量に関するデータを提供するマイクロプロセッサと、を含み、前記マイクロプロセッサは、メモリ、及びユーザーインターフェースボタンに更に接続され、前記マイクロプロセッサは、
(a)ユーザーが1日のうちのインスリンボーラス投与のための複数の時間枠から1日のうちのある時間枠を選択できるようにし、
(b)前記選択された時間枠内の前記ユーザーのためのインスリンボーラスを計算し、
(c)前記選択された時間枠を、前記マイクロプロセッサのクロックによって維持されている現在の時間枠と比較し、及び
(d)前記計算のために選択された時間枠が前記クロックの前記現在の時間枠の範囲外の場合は前記ユーザーに警告を通知する、ようにプログラムされる、糖尿病管理システム。 - 前記管理ユニットが、24時間の時間枠のうちの朝の期間、午後の期間、晩の期間、及び夜の期間に関する対応の時間間隔を画定するように構成される、請求項20に記載のシステム。
- 前記朝の期間がおよそ5am〜およそ11amと事前に画定され、前記午後の期間がおよそ11am〜およそ5pmと事前に画定され、前記晩の期間がおよそ5pm〜およそ10pmと事前に画定され、前記夜の期間がおよそ10pm〜およそ5amと事前に画定される、請求項21に記載のシステム。
- 前記マイクロプロセッサが、前記複数の時間枠のそれぞれごとのインスリン対炭水化物比、及び前記複数の時間枠のそれぞれごとのインスリン感受性値を指定するようにプログラムされる、請求項20に記載のシステム。
- 前記マイクロプロセッサが、前記複数の時間枠のそれぞれごとに、約1単位:約50gを包含する初期インスリン対炭水化物比を指定し、前記インスリン対炭水化物比の定義を通知するようにプログラムされる、請求項20に記載のシステム。
- 前記マイクロプロセッサが、前記複数の時間枠のそれぞれごとに、約1単位:1デシリットル当たり約150mgを包含する初期インスリン感受性値を指定するようにプログラムされる、請求項23に記載のシステム。
- 前記マイクロプロセッサが、前記複数の時間枠のそれぞれごとに目標血糖値を指定するように前記ユーザーによってプログラムされる、請求項20に記載のシステム。
- 前記マイクロプロセッサが、前記複数の時間枠のそれぞれごとに、1デシリットル当たり約240mgを包含する初期目標血糖値を指定するようにプログラムされる、請求項20に記載のシステム。
- 前記マイクロプロセッサが、前記複数の時間枠のそれぞれごとに、インスリン対炭水化物比、インスリン感受性係数値、及び目標血糖値を指定するようにプログラムされる、請求項20に記載のシステム。
- 前記マイクロプロセッサが、前記マイクロプロセッサの現在時刻が前記選択された時間枠の範囲外であるという文字情報を前記ディスプレイに表示するようにプログラムされる、請求項20に記載のシステム。
- 前記マイクロプロセッサが、前記フラグ付けが選択された時間枠と一致しないという文字情報を前記ディスプレイに表示するようにプログラムされる、請求項20に記載のシステム。
- 前記マイクロプロセッサが、測定されたグルコースの濃度が所定の値よりも低い場合は前記インスリンボーラスの計算を行わないようにプログラムされる、請求項20に記載のシステム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30819610P | 2010-02-25 | 2010-02-25 | |
US61/308,196 | 2010-02-25 | ||
PCT/US2010/040440 WO2011106030A1 (en) | 2010-02-25 | 2010-06-29 | Analyte testing method and system with safety warnings for insulin dosing |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013520279A JP2013520279A (ja) | 2013-06-06 |
JP5744919B2 true JP5744919B2 (ja) | 2015-07-08 |
Family
ID=42587912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012554980A Expired - Fee Related JP5744919B2 (ja) | 2010-02-25 | 2010-06-29 | インスリン投与の際の安全警告を備えた分析物試験方法及びシステム |
Country Status (10)
Country | Link |
---|---|
US (1) | US20110205065A1 (ja) |
EP (1) | EP2538834A1 (ja) |
JP (1) | JP5744919B2 (ja) |
KR (1) | KR20120120466A (ja) |
CN (1) | CN102802522B (ja) |
AU (1) | AU2010346624A1 (ja) |
BR (1) | BR112012021437A2 (ja) |
CA (1) | CA2790912A1 (ja) |
RU (1) | RU2012140732A (ja) |
WO (1) | WO2011106030A1 (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080228056A1 (en) | 2007-03-13 | 2008-09-18 | Michael Blomquist | Basal rate testing using frequent blood glucose input |
US7751907B2 (en) | 2007-05-24 | 2010-07-06 | Smiths Medical Asd, Inc. | Expert system for insulin pump therapy |
US8221345B2 (en) | 2007-05-30 | 2012-07-17 | Smiths Medical Asd, Inc. | Insulin pump based expert system |
US20090177147A1 (en) | 2008-01-07 | 2009-07-09 | Michael Blomquist | Insulin pump with insulin therapy coaching |
US20090177142A1 (en) | 2008-01-09 | 2009-07-09 | Smiths Medical Md, Inc | Insulin pump with add-on modules |
WO2011014704A2 (en) | 2009-07-30 | 2011-02-03 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US8882701B2 (en) | 2009-12-04 | 2014-11-11 | Smiths Medical Asd, Inc. | Advanced step therapy delivery for an ambulatory infusion pump and system |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9238100B2 (en) | 2012-06-07 | 2016-01-19 | Tandem Diabetes Care, Inc. | Device and method for training users of ambulatory medical devices |
JP5599857B2 (ja) * | 2012-10-01 | 2014-10-01 | アンリツ株式会社 | 移動端末試験装置及び移動端末試験方法 |
US20140129151A1 (en) | 2012-11-07 | 2014-05-08 | Dexcom, Inc. | Systems and methods for managing glycemic variability |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US10016561B2 (en) | 2013-03-15 | 2018-07-10 | Tandem Diabetes Care, Inc. | Clinical variable determination |
US9710604B2 (en) * | 2013-06-27 | 2017-07-18 | Lifescan, Inc. | Analyte meter with operational range configuration technique |
US9529503B2 (en) | 2013-06-27 | 2016-12-27 | Lifescan Scotland Limited | Analyte-measurement system recording user menu choices |
CN103495231A (zh) * | 2013-10-16 | 2014-01-08 | 李秀 | 智能药物释放装置 |
CN103495232A (zh) * | 2013-10-16 | 2014-01-08 | 李秀 | 智能药物释放装置 |
WO2015100340A1 (en) | 2013-12-26 | 2015-07-02 | Tandem Diabetes Care, Inc. | Safety processor for wireless control of a drug delivery device |
EP3086828B1 (en) | 2013-12-26 | 2023-08-09 | Tandem Diabetes Care, Inc. | Integration of infusion pump with remote electronic device |
CA2938078C (en) | 2014-01-31 | 2019-06-11 | Trustees Of Boston University | Offline glucose control based on preceding periods |
US20150289823A1 (en) * | 2014-04-10 | 2015-10-15 | Dexcom, Inc. | Glycemic urgency assessment and alerts interface |
SG11201609966SA (en) | 2014-06-03 | 2016-12-29 | Amgen Inc | Drug delivery system and method of use |
US9669160B2 (en) | 2014-07-30 | 2017-06-06 | Tandem Diabetes Care, Inc. | Temporary suspension for closed-loop medicament therapy |
EP3848072A1 (en) | 2014-12-19 | 2021-07-14 | Amgen Inc. | Drug delivery device with proximity sensor |
EP3689394A1 (en) | 2014-12-19 | 2020-08-05 | Amgen Inc. | Drug delivery device with live button or user interface field |
US10569016B2 (en) | 2015-12-29 | 2020-02-25 | Tandem Diabetes Care, Inc. | System and method for switching between closed loop and open loop control of an ambulatory infusion pump |
WO2018111928A1 (en) | 2016-12-12 | 2018-06-21 | Mazlish Bryan | Alarms and alerts for medication delivery devices and related systems and methods |
EP3559839A1 (en) * | 2016-12-23 | 2019-10-30 | Sanofi-Aventis Deutschland GmbH | Data management unit for supporting health control |
JP7196077B2 (ja) | 2016-12-23 | 2022-12-26 | サノフィ-アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 健康管理を支えるためのデータ管理ユニット |
US11033682B2 (en) * | 2017-01-13 | 2021-06-15 | Bigfoot Biomedical, Inc. | Insulin delivery methods, systems and devices |
US10881792B2 (en) | 2017-01-13 | 2021-01-05 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
WO2019125932A1 (en) * | 2017-12-21 | 2019-06-27 | Eli Lilly And Company | Closed loop control of physiological glucose |
WO2019199952A1 (en) | 2018-04-10 | 2019-10-17 | Tandem Diabetes Care, Inc. | System and method for inductively charging a medical device |
EP3827437A1 (en) * | 2018-07-26 | 2021-06-02 | Eli Lilly and Company | Systems and methods for remote prescription of medication-dosing regimens |
CN113811951A (zh) * | 2019-02-21 | 2021-12-17 | 康帕宁医疗公司 | 用于药物剂量计算器的方法、系统和装置 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413410B1 (en) | 1996-06-19 | 2002-07-02 | Lifescan, Inc. | Electrochemical cell |
AUPN363995A0 (en) | 1995-06-19 | 1995-07-13 | Memtec Limited | Electrochemical cell |
AUPN661995A0 (en) | 1995-11-16 | 1995-12-07 | Memtec America Corporation | Electrochemical cell 2 |
US6863801B2 (en) | 1995-11-16 | 2005-03-08 | Lifescan, Inc. | Electrochemical cell |
AUPO581397A0 (en) | 1997-03-21 | 1997-04-17 | Memtec America Corporation | Sensor connection means |
DE19814219A1 (de) * | 1998-03-31 | 1999-10-07 | Roche Diagnostics Gmbh | Verfahren zur Kontrolle der Insulinmedikation |
US6475372B1 (en) | 2000-02-02 | 2002-11-05 | Lifescan, Inc. | Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations |
US6193873B1 (en) | 1999-06-15 | 2001-02-27 | Lifescan, Inc. | Sample detection to initiate timing of an electrochemical assay |
JP2001017542A (ja) * | 1999-07-08 | 2001-01-23 | Ichiro Takai | インスリン注射指導装置 |
US6716577B1 (en) | 2000-02-02 | 2004-04-06 | Lifescan, Inc. | Electrochemical test strip for use in analyte determination |
US6749887B1 (en) | 2001-11-28 | 2004-06-15 | Lifescan, Inc. | Solution drying system |
US6744350B2 (en) * | 2002-02-28 | 2004-06-01 | Smiths Medical Md, Inc. | Insulin pump having missed meal bolus alarm |
US7404796B2 (en) * | 2004-03-01 | 2008-07-29 | Becton Dickinson And Company | System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
US7291256B2 (en) | 2002-09-12 | 2007-11-06 | Lifescan, Inc. | Mediator stabilized reagent compositions and methods for their use in electrochemical analyte detection assays |
DE102004011135A1 (de) * | 2004-03-08 | 2005-09-29 | Disetronic Licensing Ag | Verfahren und Vorrichtung zum Berechnen einer Bolusmenge |
ES2570993T3 (es) * | 2004-12-29 | 2016-05-23 | Lifescan Scotland Ltd | Método de introducción de datos en un dispositivo de análisis de analito |
JP4943728B2 (ja) * | 2006-03-30 | 2012-05-30 | テルモ株式会社 | 血糖計 |
EP2095282A2 (en) * | 2006-11-01 | 2009-09-02 | SHER, Philip Michael | Device for predicting and managing blood glucose concentration by analyzing the effect of, and controlling, pharmacodynamic insulin unit equivalents |
US20080235053A1 (en) * | 2007-03-20 | 2008-09-25 | Pinaki Ray | Communication medium for diabetes management |
JP5427350B2 (ja) * | 2007-10-31 | 2014-02-26 | パナソニックヘルスケア株式会社 | 傾向予測装置及び傾向予測システム |
US9839395B2 (en) * | 2007-12-17 | 2017-12-12 | Dexcom, Inc. | Systems and methods for processing sensor data |
CN102548467A (zh) * | 2008-07-18 | 2012-07-04 | 生命扫描有限公司 | 分析物测量和管理装置及相关方法 |
TWI377515B (en) * | 2008-08-14 | 2012-11-21 | Eps Bio Technology Corp | Health management device |
US20100174228A1 (en) * | 2008-10-24 | 2010-07-08 | Bruce Buckingham | Hypoglycemia prediction and control |
US8487758B2 (en) * | 2009-09-02 | 2013-07-16 | Medtronic Minimed, Inc. | Medical device having an intelligent alerting scheme, and related operating methods |
-
2010
- 2010-06-29 BR BR112012021437A patent/BR112012021437A2/pt not_active Application Discontinuation
- 2010-06-29 CN CN201080064804.8A patent/CN102802522B/zh not_active Expired - Fee Related
- 2010-06-29 RU RU2012140732/14A patent/RU2012140732A/ru not_active Application Discontinuation
- 2010-06-29 KR KR1020127024558A patent/KR20120120466A/ko not_active Application Discontinuation
- 2010-06-29 WO PCT/US2010/040440 patent/WO2011106030A1/en active Application Filing
- 2010-06-29 CA CA2790912A patent/CA2790912A1/en not_active Abandoned
- 2010-06-29 AU AU2010346624A patent/AU2010346624A1/en not_active Abandoned
- 2010-06-29 EP EP10730320A patent/EP2538834A1/en not_active Withdrawn
- 2010-06-29 US US12/826,567 patent/US20110205065A1/en not_active Abandoned
- 2010-06-29 JP JP2012554980A patent/JP5744919B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102802522A (zh) | 2012-11-28 |
BR112012021437A2 (pt) | 2016-05-31 |
JP2013520279A (ja) | 2013-06-06 |
EP2538834A1 (en) | 2013-01-02 |
AU2010346624A1 (en) | 2012-09-06 |
CA2790912A1 (en) | 2011-09-01 |
RU2012140732A (ru) | 2014-03-27 |
US20110205065A1 (en) | 2011-08-25 |
WO2011106030A1 (en) | 2011-09-01 |
KR20120120466A (ko) | 2012-11-01 |
CN102802522B (zh) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5744919B2 (ja) | インスリン投与の際の安全警告を備えた分析物試験方法及びシステム | |
JP6461885B2 (ja) | 糖尿病管理のための分析物試験方法及びデバイス | |
JP5718947B2 (ja) | 高血糖及び低血糖傾向を通知する分析物試験方法及びシステム | |
JP5635625B2 (ja) | 分析物試験方法及びシステム | |
JP5654587B2 (ja) | 基礎インスリン療法を算出する分析物試験方法及び装置 | |
US20100332445A1 (en) | Analyte testing method and system | |
WO2010091102A1 (en) | Multi-function analyte test device and methods therefor | |
AU2015202434A1 (en) | Analyte testing method and system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130516 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140320 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140408 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140708 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140715 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140808 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140815 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140904 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150407 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150430 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5744919 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |